Angela Webb

Angela Webb

Auto-generated profile, based on publicly available information

Angela Webb

Peter MacCallum Cancer Centre Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2020 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
GWGwyneth Natalie Wong
Gwyneth Natalie Wong
AWAngela Webb
Angela Webb
DGDavid E. Gyorki
David E. Gyorki
CMChris McCormack
Chris McCormack
PTPhillip Tran
Phillip Tran
MHMichael Henderson
Michael Henderson

10 June 2016 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
PDF file
VEVanessa Estall
Vanessa Estall
AAAngela Allen
Angela Allen
AWAngela Webb
Angela Webb
MBMathias Bressel
Mathias Bressel
CMChris McCormack
Chris McCormack
JSJohn Spillane
John Spillane
Background: Squamous cell carcinoma of the scalp is a common clinical problem in an aging population. Despite its high incidence, little has been documented regarding treatment or outcomes.Methods: We retrospectively analysed 235 cases treated with curative intent at Peter MaCallum Cancer Centre between 1998 and 2010. The cohort was analysed for its characteristics, management, survival and prognostic factors.Results: The patients were primarily male (88%) with a median age of 79 years (range 53–98 years). There was a high proportion of immunosuppressed patients (29%) and stage T2 (48%) tumours. Management included surgery (45%), radiotherapy (28%) and surgery and adjuvant radiotherapy (26%). Median follow up from treatment was 4.5 years. Estimated 5‐year overall survival (OS), disease‐specific survival and progression‐free survival (PFS) were 59, 94 and 51%, respectively. The 5‐year cumulative incidence of local and regional relapse was 11 and 7%, respectively. There were four patients who developed distant metastases and died of their disease. Statistically significant prognostic factors identified for poor outcomes for OS and PFS were T2 stage (hazard ratio [1.7 and 2.1) and immunosuppression (HR 3.3 and 3.4).Conclusions: We conclude the presence of immunosuppression and T2 stage is prognostic for survival. Further research to establish treatment principles is warranted.

30 March 2024 in Anz Journal of Surgery
Verified
Journal Article
Closed access
JAJoanne Au
Joanne Au
SHSam Hamilton
Sam Hamilton
AWAngela Webb
Angela Webb

21 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ALAnnette M Lim
Annette M Lim
BBBenjamin Graham Baker
Benjamin Graham Baker
PLPeter Lion
Peter Lion
CAChristopher M. Angel
Christopher M. Angel
JSJennifer Simmons
Jennifer Simmons
DRDanny Rischin
Danny Rischin
Background: A previous published Phase 2 trial using 2–4 doses of neoadjuvant cemiplimab in stage II–IV resectable cutaneous squamous cell carcinoma (CSCC) demonstrated that a complete pathological (pCR) rate of 51% and major pathological response (mPR) rate of 13% could be achieved with durable disease control. Methods: In this open-label, single-institution phase II trial (NCT05878288), patients with stage II–IV resectable CSCC received up to four doses of neoadjuvant cemiplimab prior to surgery. The primary endpoint of the study was to perform comprehensive molecular profiling. The focus of this report are the secondary clinical endpoints of pCR rate, mPR (defined as <10% viable tumour) rate, overall response rate (ORR) using Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, immune-modified RECIST (imRECIST) and Immune PET Response Criteria in Solid Tumours (iPERCIST), disease-free survival (DFS), overall survival (OS), safety, and to describe changes in planned surgery. Results: Eleven patients were enrolled, with all proceeding with surgery. An ORR and pCR rate of 73% (8/11; 95% CI 0.39–0.93) was achieved, whilst 3/11 patients progressed on treatment. On pre-operative imaging, all 8/11 pCR patients demonstrated a partial response (RECIST 1.1), whilst 6/8 achieved a complete metabolic response and 2/8 a partial metabolic response (iPERCIST). Median follow-up was 10.2 (IQR 6.7–16.4) months. DFS was 91% (95% CI 0.57–1) and OS was 100% (95% CI 0.68–1), with one non-responder patient who developed recurrent locoregional and distant metastatic disease. There were no unexpected safety signals. Pathological features of response to neoadjuvant immunotherapy most commonly were granulomatous inflammation with keratin, fibrosis and inflammation. No cases with a dense inflammatory infiltrate were observed. Neoadjuvant immunotherapy did not impact the intra-operative planning and execution of surgery, but in the eight pCR cases, it reduced the extent of required surgery, whilst in the three non-responder cases, surgery was more extensive than originally planned. Conclusions: The DISCERN trial confirms that an excellent complete response rate can be achieved with four doses of neoadjuvant immunotherapy in stage II–IV CSCC. Proposed refinements to the pathological assessment of response and metabolic response criteria in CSCC for the neoadjuvant context are provided.

7 March 2024 in Anz Journal of Surgery
Verified
Journal Article
Closed access
MDMaxim Devine
Maxim Devine
MEMark Edmondson
Mark Edmondson
PGPeter Gearing
Peter Gearing
ECElizabeth Concannon
Elizabeth Concannon
MFMichael Findlay
Michael Findlay
AWAngela Webb
Angela Webb

9 November 2021 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
PDF file
NBNicholas W Bucknell
Nicholas W Bucknell
DGDavid E. Gyorki
David E. Gyorki
MBMathias Bressel
Mathias Bressel
VEVanessa Estall
Vanessa Estall
AWAngela Webb
Angela Webb
ATAlbert Tiong
Albert Tiong
Purpose: This study examined the clinical outcomes and prognostic factors of patients with metastatic cutaneous SCC metastatic to the axilla and groin when managed with curative‐intent lymphadenectomy and received (neo)adjuvant treatment.Methods and Materials: We conducted a single institution retrospective review. Patients who had nodal disease without distant spread were 18 years or older with no non‐cutaneous primary identified.Results: From January 2000 to July 2015, 78 patients were treated for axilla (64, 82%) or inguinal (14, 18%) involvement with cSCC. The median age was 75.5 years (range: 29–95), and 8 patients (11%) were immunosuppressed. The median size of the largest node was 45 mm (range: 8–135), and extracapsular extension was found in 63 (81%) cases. A majority of patients were treated with surgery alone (21, 26.9%) and surgery with adjuvant radiation therapy (54, 69%). The 2‐year OS and PFS were 50% (95% CI: 40%–63%) and 43% (95% CI: 33%–56%), and 5‐year OS and PFS were 33% (95% CI:23%–47%) and 32% (95% CI:22%–46%) respectively in the entire cohort. On univariable analysis, factors associated with longer OS were as follows: younger age (HR 1.1, 95% CI: 0.9–1.3 P = 0.021), improved performance status (HR 1.5, 95% CI:1.0–2.3 P = 0.026), lack of immunosuppression (HR 3.3, 95% CI: 1.5–7.3 P = 0.001), lower lymph node ratio (HR 1.2, 95% CI:1.0–1.3 P = 0.007), lower number of positive nodes (HR 1.1, 95% CI:1.0–1.2 P = 0.004) and the use of radiation therapy (HR 0.5, 95% CI:0.3–0.9 P = 0.012).Conclusion: Metastasis to the axilla and groin with cSCC has poor outcomes with standard treatment. The addition of immunotherapy warrants investigation.